Background. Vonoprazan affords more clinical benefits than proton pump inhibitors (PPIs) during the healing of gastroduodenal ulcers. However, it remains controversial whether vonoprazan is more effective than PPIs when used to heal artificial ulcers arising after endoscopic submucosal dissection (ESD). Aim. This study investigated the effects of vonoprazan compared with esomeprazole on the healing of post-ESD artificial ulcers. Methods. Sixty patients who underwent gastric ESD between May 2015 and May 2017 were randomized to treatment with vonoprazan (V group) or esomeprazole (E group) for 8 weeks. Upper endoscopy was performed at 4 and 8 weeks after ESD, and drug effects were estimated based on the ulcer healing rates and shrinkage rates....
Antithrombotic therapy is a major risk factor for delayed bleeding after endoscopic submucosal disse...
Background: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors ...
BACKGROUND: The efficacy of proton pump inhibitors in patients at high risk of gastrointestinal inju...
Vonoprazan is a potent inhibitor of gastric acid secretion and may have better response than proton ...
Background/Aims Vonoprazan is a new a potassium-competitive acid blocker (P-CAB) that was recently d...
BackgroundThe comparative efficacy of various anti-ulcer medications after gastric endoscopic submuc...
Goals: We assessed the efficacy of polaprezinc plus proton pump inhibitor (PPI) treatment for endosc...
Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent a novel and heterogeneou...
Vonoprazan is a novel potassium-competitive acid blocker that has been introduced as an effective tr...
Objective. To contrast the effect of rebamipide with proton pump inhibitors (PPIs) versus PPIs alone...
Gastric endoscopic submucosal dissection (ESD) causes artificial gastric ulcers and there is no cons...
BACKGROUND: Acid suppressing agents are widely used to treat the iatrogenic ulcers following endosco...
Background : /Aims: Although intravenous proton pump inhibitor (PPI) has been used for the preventio...
Abstract: [Aim] The efficacy of pre-procedure oral proton pump inhibitor (PPI) administration for g...
[Aim] The efficacy of pre-procedure oral proton pump inhibitor (PPI) administration for gastric endo...
Antithrombotic therapy is a major risk factor for delayed bleeding after endoscopic submucosal disse...
Background: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors ...
BACKGROUND: The efficacy of proton pump inhibitors in patients at high risk of gastrointestinal inju...
Vonoprazan is a potent inhibitor of gastric acid secretion and may have better response than proton ...
Background/Aims Vonoprazan is a new a potassium-competitive acid blocker (P-CAB) that was recently d...
BackgroundThe comparative efficacy of various anti-ulcer medications after gastric endoscopic submuc...
Goals: We assessed the efficacy of polaprezinc plus proton pump inhibitor (PPI) treatment for endosc...
Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent a novel and heterogeneou...
Vonoprazan is a novel potassium-competitive acid blocker that has been introduced as an effective tr...
Objective. To contrast the effect of rebamipide with proton pump inhibitors (PPIs) versus PPIs alone...
Gastric endoscopic submucosal dissection (ESD) causes artificial gastric ulcers and there is no cons...
BACKGROUND: Acid suppressing agents are widely used to treat the iatrogenic ulcers following endosco...
Background : /Aims: Although intravenous proton pump inhibitor (PPI) has been used for the preventio...
Abstract: [Aim] The efficacy of pre-procedure oral proton pump inhibitor (PPI) administration for g...
[Aim] The efficacy of pre-procedure oral proton pump inhibitor (PPI) administration for gastric endo...
Antithrombotic therapy is a major risk factor for delayed bleeding after endoscopic submucosal disse...
Background: Standard treatment for patients with erosive esophagitis (EE) is proton-pump inhibitors ...
BACKGROUND: The efficacy of proton pump inhibitors in patients at high risk of gastrointestinal inju...